Site-specific incorporation of three toll-like receptor 2 targeting adjuvants into semisynthetic, molecularly defined nanoparticles: application to group a streptococcal vaccines.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Bioconjugate chemistry

• Publication date

  2014-04-18

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/bc500108bPMID 24712905
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Key roles of adjuvants in modern vaccines

  2013cited by this paper
• Progress Toward a Global Group A Streptococcal Vaccine

  2013cited by this paper
• Long-Term Antibody Memory Induced by Synthetic Peptide Vaccination Is Protective against Streptococcus pyogenes Infection and Is Independent of Memory T Cell Help

  2013cited by this paper
• Group A streptococcal vaccines: paving a path for accelerated development.

  2013cited by this paper
• Updated model of group A Streptococcus M proteins based on a comprehensive worldwide study.

  2013cited by this paper
• An efficient, chemically-defined semisynthetic lipid-adjuvanted nanoparticulate vaccine development system.

  2013cited by this paper
• Design and development of stable, water-soluble, human Toll-like receptor 2 specific monoacyl lipopeptides as candidate vaccine adjuvants.

  2013cited by this paper
• Applications of nanotechnology for immunology

  2013cited by this paper
• Modern Subunit Vaccines: Development, Components, and Research Opportunities

  2013cited by this paper
• A totally synthetic lipopeptide-based self-adjuvanting vaccine induces neutralizing antibodies against heat-stable enterotoxin from enterotoxigenic Escherichia coli.

  2012cited by this paper
• Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates

  2012cited by this paper
• Recent progress in mucosal vaccine development: potential and limitations

  2012cited by this paper
• TLR ligand-peptide conjugate vaccines: toward clinical application.

  2012cited by this paper
• Immunological Evaluation of Lipopeptide Group A Streptococcus (GAS) Vaccine: Structure-Activity Relationship

  2012cited by this paper
• Vaccines: From Empirical Development to Rational Design

  2012cited by this paper
• Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial.

  2012cited by this paper
• Molecular insight into invasive group A streptococcal disease

  2011cited by this paper
• New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci.

  2011cited by this paper
• Lipidation of intact proteins produces highly immunogenic vaccine candidates.

  2011cited by this paper
• Immunological mechanisms of vaccination

  2011cited by this paper
• Tunable degradation of maleimide-thiol adducts in reducing environments.

  2011cited by this paper
• Structure-activity relationships in toll-like receptor 2-agonists leading to simplified monoacyl lipopeptides.

  2011cited by this paper
• Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns

  2010cited by this paper
• Design of three-component vaccines against group A streptococcal infections: importance of spatial arrangement of vaccine components.

  2010cited by this paper
• Structure-activity relationship of lipopeptide Group A streptococcus (GAS) vaccine candidates on toll-like receptor 2.

  2010cited by this paper
• Synthesis of N alpha-Fmoc protected derivatives of S-(2,3-dihydroxypropyl)-cysteine and their application in peptide synthesis.

  2009cited by this paper
• Global emm type distribution of group A streptococci: systematic review and implications for vaccine development.

  2009cited by this paper
• Group A streptococcal vaccines: facts versus fantasy

  2009cited by this paper
• Total chemical synthesis of proteins.

  2009cited by this paper
• Moving forward: a mucosal vaccine against group A streptococcus

  2009cited by this paper
• Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer.

  2009cited by this paper
• Synthesis of cyclic peptides through direct aminolysis of peptide thioesters catalyzed by imidazole in aqueous organic solutions.

  2009cited by this paper
• A novel technology for the production of a heterologous lipoprotein immunogen in high yield has implications for the field of vaccine design.

  2009cited by this paper
• Synthesis of toll-like receptor-2 targeting lipopeptides as self-adjuvanting vaccines.

  2008cited by this paper
• Free-radical-based, specific desulfurization of cysteine: a powerful advance in the synthesis of polypeptides and glycopolypeptides.

  2007cited by this paper
• Intratumoural injection of the toll-like receptor-2/6 agonist ‘macrophage-activating lipopeptide-2’ in patients with pancreatic carcinoma: a phase I/II trial

  2007cited by this paper
• Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide.

  2007cited by this paper
• Synthetic virus-like particles from self-assembling coiled-coil lipopeptides and their use in antigen display to the immune system.

  2007cited by this paper
• Insights into the mechanism and catalysis of the native chemical ligation reaction.

  2006cited by this paper
• Preparation and evaluation of unimolecular pentavalent and hexavalent antigenic constructs targeting prostate and breast cancer: a synthetic route to anticancer vaccine candidates.

  2006cited by this paper
• Synthesis of a highly pure lipid core peptide based self-adjuvanting triepitopic group A streptococcal vaccine, and subsequent immunological evaluation.

  2006cited by this paper
• M protein conserved region antibodies opsonise multiple strains of Streptococcus pyogenes with sequence variations in C-repeats.

  2005cited by this paper
• Peptides Identified through Phage Display Direct Immunogenic Antigen to Dendritic Cells1

  2004cited by this paper
• Lipopeptide epitopes extended by an Nϵ‐palmitoyl‐lysine moiety increase uptake and maturation of dendritic cells through a Toll‐like receptor‐2 pathway and trigger a Th1‐dependent protective immunity

  2004cited by this paper
• Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8- and diphtheria toxoid-specific antibodies to protection.

  2003cited by this paper
• Highly Immunogenic and Totally Synthetic Lipopeptides as Self-Adjuvanting Immunocontraceptive Vaccines1

  2002cited by this paper
• Evaluation of a Lipopeptide Immunogen as a Therapeutic in HIV Type 1-Seropositive Individuals

  2000cited by this paper
• New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population

  2000cited by this paper
• Totally synthetic lipid-containing polyoxime peptide constructs are potent immunogens.

  2000cited by this paper
• Protein engineering by expressed protein ligation.

  2000cited by this paper
• Accelerated chemical synthesis of peptides and small proteins.

  1999cited by this paper
• Expressed protein ligation: a general method for protein engineering.

  1998cited by this paper
• Semisynthesis of cytotoxic proteins using a modified protein splicing element

  1998cited by this paper
• Mapping the minimal murine T cell and B cell epitopes within a peptide vaccine candidate from the conserved region of the M protein of group A streptococcus.

  1997cited by this paper
• Synthesis of proteins by native chemical ligation.

  1994cited by this paper
• Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides.

  1994cited by this paper
• Lymphocyte life-span and memory.

  1994cited by this paper
• Maintenance of B-cell memory by long-lived cells generated from proliferating precursors

  1990cited by this paper

• Adjuvant Templating Improves On-Target/Off-Target Antibody Ratio Better than Linker Addition for M2-Derived Peptide Amphiphile Micelle Vaccines

  2025cites this paper
• Multifunctional Lipidated Protein Carrier with a Built-In Adjuvant as a Universal Vaccine Platform Potently Elevates Immunogenicity of Weak Antigens.

  2024cites this paper
• Cyclic Peptide Conjugate Vaccines and Physically Mixed Cyclic Peptide Vaccines for Subcutaneous Immunization.

  2024cites this paper
• Incorporation of a Toll-like receptor 2/6 agonist potentiates mRNA vaccines against cancer and infectious diseases

  2023cites this paper
• Self-Adjuvanting Protein Vaccine Conjugated with a Novel Synthetic TLR4 Agonist on Virus-Like Liposome Induces Potent Immunity against SARS-CoV-2

  2023cites this paper
• The influence of component structural arrangement on peptide vaccine immunogenicity.

  2022cites this paper
• Structure-activity relationship of lipid, cyclic peptide and antigen rearrangement of physically mixed vaccines.

  2022cites this paper
• Emerging peptide-based nanovaccines: From design synthesis to defense against cancer and infection.

  2022cites this paper
• New modular platform based on multi-adjuvanted amphiphilic chitosan nanoparticles for efficient lipopeptide vaccine delivery against group A streptococcus

  2022cites this paper
• Current Prospects in Peptide-Based Subunit Nanovaccines.

  2021cites this paper
• Built-in adjuvants for use in vaccines.

  2021cites this paper
• Poly(hydrophobic amino acid) Conjugates for the Delivery of Multiepitope Vaccine against Group A Streptococcus.

  2021cites this paper
• Programmable Membrane-Mediated Attachment of Synthetic Virus-like Nanoparticles on Artificial Protocells for Enhanced Immunogenicity

  2021cites this paper
• Developments in Vaccine Adjuvants.

  2021cites this paper
• Lipid-Based Nanoparticles for Delivery of Vaccine Adjuvants and Antigens: Toward Multicomponent Vaccines.

  2021cites this paper
• Mimicking Native Display of CD0873 on Liposomes Augments Its Potency as an Oral Vaccine against Clostridioides difficile

  2021cites this paper
• TLR2 Agonistic Small Molecules: Detailed Structure-Activity Relationship, Applications, and Future Prospects.

  2020cites this paper
• A Self-Adjuvanting Vaccine Platform: Optimization of Site-Specific Sortase A-Mediated Conjugation of Toll-like Receptor 2 Ligands onto the C- or N- terminus of Recombinant Antigens.

  2020cites this paper
• Modulation of immune responses with nanoparticles and reduction of their immunotoxicity.

  2020cites this paper
• Development of an Enzyme-Mediated, Site-Specific Method to Conjugate Toll-Like Receptor 2 Agonists onto Protein Antigens: Towards a Broadly Protective, Four Component, Group A Streptococcal Self-Adjuvanting Lipoprotein-Fusion Combination Vaccine.

  2020cites this paper
• Lipoprotein-based drug delivery.

  2020cites this paper
• 1 TLR Agonist Conjugation : A Chemical Perspective

  2019cites this paper
• Recent Advances in the Development of Peptide Vaccines and Their Delivery Systems against Group A Streptococcus

  2019cites this paper
• Application of built-in adjuvants for epitope-based vaccines

  2019cites this paper
• Semisynthetic, self-adjuvanting vaccine development: Efficient, site-specific sortase A-mediated conjugation of Toll-like receptor 2 ligand FSL-1 to recombinant protein antigens under native conditions and application to a model group A streptococcal vaccine.

  2019cites this paper
• Immunomodulatory Nanosystems

  2019cites this paper
• Amyloid self‐assembling peptides: Potential applications in nanovaccine engineering and biosensing

  2018cites this paper
• Toll-like Receptor Agonist Conjugation: A Chemical Perspective.

  2018cites this paper
• Vaccine Adjuvant Incorporation Strategy Dictates Peptide Amphiphile Micelle Immunostimulatory Capacity

  2018cites this paper
• Lipids as activators of innate immunity in peptide vaccine delivery.

  2018cites this paper
• Advances and Opportunities in Nanoparticle‐ and Nanomaterial‐Based Vaccines against Bacterial Infections

  2018cites this paper
• Biodegradable Micelles Based on Poly(ethylene glycol)-b-polylipopeptide Copolymer: A Robust and Versatile Nanoplatform for Anticancer Drug Delivery.

  2017cites this paper
• Biotechnology approaches to produce potent, self-adjuvanting antigen-adjuvant fusion protein subunit vaccines.

  2017cites this paper
• Bioconjugation Approaches to Producing Subunit Vaccines Composed of Protein or Peptide Antigens and Covalently Attached Toll-Like Receptor Ligands.

  2017cites this paper
• Self‐Assembled Nano‐Immunostimulant for Synergistic Immune Activation

  2017cites this paper
• Bivalent mucosal peptide vaccines administered using the LCP carrier system stimulate protective immune responses against Streptococcus pyogenes infection.

  2017cites this paper
• Synthesis of Multicomponent Peptide-Based Vaccine Candidates against Group A Streptococcus

  2017cites this paper
• Nanosized, peptide-based multicomponent DNA delivery systems: optimization of endosome escape activity.

  2016cites this paper
• Towards the next generation of biomedicines by site-selective conjugation.

  2016cites this paper
• Mannosylated lipopetides as model vaccines for targeting the mannose receptor

  2016cites this paper
• Synthesis and evaluation of fluorescent Pam3Cys peptide conjugates.

  2016cites this paper
• Glycopeptide Nanoconjugates Based on Multilayer Self-Assembly as an Antitumor Vaccine.

  2015cites this paper
• Self-adjuvanting lipoimmunogens for therapeutic HPV vaccine development: potential clinical impact

  2015cites this paper
• Guiding principles in the design of molecular bioconjugates for vaccine applications.

  2015cites this paper
• Combined synthetic and recombinant techniques for the development of lipoprotein-based, self-adjuvanting vaccines targeting human papillomavirus type-16 associated tumors.

  2015cites this paper
• Recent advances in the molecular design of synthetic vaccines.

  2015cites this paper
• Progress in Vaccine Development

  2015cites this paper
• Peptide-based synthetic vaccines

  2015cites this paper
• The Current Opinion of Pathogenesis and Antimicrobial Resistance ofStreptococcus pyogenes

  2014cites this paper